EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Essex Bio-Technology (1061.HK) 2025 Annual Results at a glance

2026.03.23

Essex Bio-Technology Reports Robust Results for FY2025. Turnover Soars 8.6% to HK$1814 million. Net Profit up 3.5% to HK$ 318.1 million. Total Dividend Increases by 16.7% to HK14 Cents per Share. Multiple Regulatory Approvals and Strategic Collaborations Strengthened Market Position.

2026.03.23

Date

Title

2024-08-26

Essex Bio-Technology Included in Forbes Asia's Best Under A Billion 2024

2024-08-14

Preservative-free Unit-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China

2024-06-27

EssexBio has climbed 13 places over the previous year in “China Pharmaceutical Industry Top 100 Series List” & Beifushu® awarded “China Pharmaceutical Brands List” for the sixth consecutive year

2024-03-19

Essex Bio-Technology (1061.HK) 2023 Annual Results at a glance

2024-03-18

Essex Bio-Technology Posts Sound 2023 Annual Financial Results: Revenue Up 29.5%, Profit Up 22.1%

2024-01-03

Change of Address of Head Office and Principal Place of Business in Hong Kong

2023-08-16

Essex Bio-Technology (1061.HK) 2023 Interim Results at a glance

2023-08-16

Essex Bio-Technology Posts Sound 2023 Interim Financial Results Revenue Up 37.1%, Profit Up 22%

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT